Kewaunee Scientific Co. (NASDAQ:KEQU) CEO Sells $59,819.36 in Stock

Kewaunee Scientific Co. (NASDAQ:KEQU) CEO Thomas David Hull III sold 1,844 shares of the firm’s stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $32.44, for a total transaction of $59,819.36. Following the completion of the sale, the chief executive officer now directly owns 36,072 shares of the company’s stock, valued at approximately $1,170,175.68. The trade was a 4.86 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Thomas David Hull III also recently made the following trade(s):

• On Monday, March 24th, Thomas David Hull III sold 3,000 shares of Kewaunee Scientific stock. The stock was sold at an average price of $45.63, for a total transaction of $136,890.00.
• On Friday, March 21st, Thomas David Hull III sold 213 shares of Kewaunee Scientific stock. The stock was sold at an average price of $48.53, for a total transaction of $10,336.89.

Kewaunee Scientific Stock Down 3.3 %

Kewaunee Scientific stock traded down $1.09 during trading hours on Monday, reaching $32.15. The stock had a trading volume of 41,778 shares, compared to its average volume of 23,781. The company has a market cap of $91.79 million, a price-to-earnings ratio of 5.10 and a beta of 0.59. The business’s 50 day moving average price is $49.68 and its 200-day moving average price is $47.45. Kewaunee Scientific Co. has a 52 week low of $30.82 and a 52 week high of $71.33. The company has a debt-to-equity ratio of 0.45, a current ratio of 2.64 and a quick ratio of 2.13.

Kewaunee Scientific (NASDAQ:KEQU) last issued its quarterly earnings data on Wednesday, March 12th. The technology company reported $1.09 earnings per share (EPS) for the quarter. The firm had revenue of $67.17 million for the quarter. Kewaunee Scientific had a net margin of 9.39% and a return on equity of 25.83%.

Wall Street Analyst Weigh In

Separately, StockNews.com downgraded shares of Kewaunee Scientific from a “buy” rating to a “hold” rating in a research report on Friday, March 14th.

Institutional Trading of Kewaunee Scientific

Institutional investors have recently made changes to their positions in the business. Bank of America Corp DE boosted its holdings in Kewaunee Scientific by 2,605.9% in the fourth quarter. Bank of America Corp DE now owns 460 shares of the technology company’s stock worth $28,000 after acquiring an additional 443 shares in the last quarter. IFP Advisors Inc purchased a new position in shares of Kewaunee Scientific in the 4th quarter valued at approximately $36,000. O Shaughnessy Asset Management LLC boosted its stake in Kewaunee Scientific by 3.3% in the 4th quarter. O Shaughnessy Asset Management LLC now owns 28,008 shares of the technology company’s stock worth $1,733,000 after purchasing an additional 891 shares in the last quarter. JPMorgan Chase & Co. grew its position in Kewaunee Scientific by 18,000.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 905 shares of the technology company’s stock worth $30,000 after purchasing an additional 900 shares during the last quarter. Finally, Ritholtz Wealth Management increased its stake in Kewaunee Scientific by 15.6% during the 4th quarter. Ritholtz Wealth Management now owns 12,619 shares of the technology company’s stock valued at $781,000 after purchasing an additional 1,706 shares in the last quarter. Institutional investors and hedge funds own 32.69% of the company’s stock.

About Kewaunee Scientific

Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products. The company operates through two segments, Domestic and International. Its products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks.